Eli Lilly

Mike Grey appointed Executive Chair of Theolytics' Board of Directors

Retrieved on: 
Thursday, March 21, 2024
Ovarian cancer, Eli Lilly, Chair, Biotechnology, Patient, Drug development, Potyvirus, Corporate development, Pharmaceutical industry

OXFORD, England, March 21, 2024 /PRNewswire/ -- Theolytics, a biotechnology company developing category changing cancer therapies in the form of oncolytic viruses, today announced the appointment of Michael (Mike) Grey succeeding Dr. Ken Powell, who is retiring from the Board having served as Chair since 2019.

Key Points: 
  • THEO-260 is an oncolytic adenovirus that has demonstrated compelling efficacy in preclinical studies, selected to be effective in stromal-rich solid tumors, combined with systemic, intravenous delivery potential.
  • "Mike brings a wealth of experience to Theolytics" said Charlotte Casebourne Stock, Chief Executive Officer of Theolytics.
  • "I am delighted to be joining Theolytics at this important time, as our lead programme is scheduled to start clinical studies mid-2024" said Mike Grey, Executive Chair of the Board of Directors at Theolytics.
  • Mike has founded several biotechnology companies and is currently Chair/Executive Chair of Mirum Pharmaceuticals, Inc., Sorriso Pharmaceuticals, Inc., Reneo Pharmaceuticals, Inc., Spruce Biosciences, Inc. and Plexium Inc.

Mike Grey appointed Executive Chair of Theolytics' Board of Directors

Retrieved on: 
Thursday, March 21, 2024
Ovarian cancer, Eli Lilly, Chair, Biotechnology, Patient, Drug development, Potyvirus, Corporate development, Pharmaceutical industry

OXFORD, England, March 21, 2024 /PRNewswire/ -- Theolytics, a biotechnology company developing category changing cancer therapies in the form of oncolytic viruses, today announced the appointment of Michael (Mike) Grey succeeding Dr. Ken Powell, who is retiring from the Board having served as Chair since 2019.

Key Points: 
  • THEO-260 is an oncolytic adenovirus that has demonstrated compelling efficacy in preclinical studies, selected to be effective in stromal-rich solid tumors, combined with systemic, intravenous delivery potential.
  • "Mike brings a wealth of experience to Theolytics" said Charlotte Casebourne Stock, Chief Executive Officer of Theolytics.
  • "I am delighted to be joining Theolytics at this important time, as our lead programme is scheduled to start clinical studies mid-2024" said Mike Grey, Executive Chair of the Board of Directors at Theolytics.
  • Mike has founded several biotechnology companies and is currently Chair/Executive Chair of Mirum Pharmaceuticals, Inc., Sorriso Pharmaceuticals, Inc., Reneo Pharmaceuticals, Inc., Spruce Biosciences, Inc. and Plexium Inc.

Summary of opinion: Retsevmo Positive

Retrieved on: 
Wednesday, April 3, 2024
Civil service commission, Eli Lilly, NSCLC, MTC, Committee, RET, Lung cancer, Medication package insert, Selpercatinib, Iodine, European Commission, Marketing, CHMP, Medullary thyroid cancer

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Retsevmo.

Key Points: 
  • On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Retsevmo.
  • The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V.
  • The CHMP adopted a new indication as follows:
    Retsevmo as monotherapy is indicated for the treatment of adults with:
    - advanced RET fusion-positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1).
  • 1New text in bold.

4BIO Capital Strengthens Advisory Board and Investment Team

Retrieved on: 
Monday, March 11, 2024
Eli Lilly, University, Advisory board, AstraZeneca, Philosophy, Doctor of Philosophy, GSK, CSL, Growth, Sale, Government, Vaccine, Therapy, CSL Vifor, Associate, VVMF, Admiration, NSW, Pharmaceutical industry

LONDON, 11 March 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, announces today the appointments of biopharmaceutical industry veteran Abbas Hussain and world-leading vectorology expert Leszek Lisowski, PhD MBA to its Advisory Board.

Key Points: 
  • LONDON, 11 March 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, announces today the appointments of biopharmaceutical industry veteran Abbas Hussain and world-leading vectorology expert Leszek Lisowski, PhD MBA to its Advisory Board.
  • Along with the appointment of Abbas and Leszek, 4BIO is also pleased to announce the promotion of Dr Natalie Johnston to Principal.
  • I am honoured to be joining the 4BIO Capital Advisory Board alongside such esteemed members and look forward to working closely with the entire team to support the firm’s portfolio companies and identify the disruptive companies of the future.”
    Leszek Lisowski, newly appointed Advisory Board member added: “I have watched the 4BIO Capital team’s success over the last 8 years with admiration and I am excited to support them as an Advisory Board member.
  • Fostering the development of our team is core to 4BIO’s philosophy, ensuring we have the very best talent to help drive tomorrow’s innovation.

FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’s

Retrieved on: 
Friday, March 8, 2024
Eli Lilly, FDA, Food, Donanemab, Disease, Patient, Pharmaceutical industry

About UsAgainstAlzheimer’sUsAgainstAlzheimer’s is engaged in a relentless pursuit to end Alzheimer’s, the sixth leading killer in America. Our work centers on prevention, early detection and diagnosis, and equal access to treatments regardless of gender, race, or ethnicity. To achieve our mission, we give voice to patients and caregivers while partnering with government, scientists, the private sector, and allied organizations -- the people who put the “Us” in UsAgainstAlzheimer’s.

Key Points: 
  • WASHINGTON, March 08, 2024 (GLOBE NEWSWIRE) -- The maker of donanemab, Eli Lilly, announced today that the Food and Drug Administration (FDA) will convene an advisory committee to consider the drug’s safety and efficacy, further delaying approval of the promising drug.
  • UsAgainstAlzheimer’s issued the following statement in response:
    “As patients, we’re obviously disappointed by any delay.
  • We know that about 2,000 people per day progress to more advanced stages of the disease, so we urge the FDA to schedule this advisory committee as soon as possible to discuss these important questions.”

Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Friday, March 8, 2024
Eli Lilly, Therapy, Research, Enzyme, CDX, PARP, Drug development, DRP, ADP, Interim, Biomarker, Ovarian cancer, Administration, Patient, Oncology, G&A, Appointment, Cancer, Pharmaceutical industry

The Company's Interim Chief Executive Officer, Thomas Jensen, stated, “2023 was a year of remarkable achievements for Allarity Therapeutics as we made significant strides in advancing our DRP®-guided drug development.

Key Points: 
  • The Company's Interim Chief Executive Officer, Thomas Jensen, stated, “2023 was a year of remarkable achievements for Allarity Therapeutics as we made significant strides in advancing our DRP®-guided drug development.
  • Announced leadership changes and strategic advisory engagement:
    Appointment of co-founder Thomas H. Jensen as Interim Chief Executive Officer in December 2023.
  • With nearly two decades at Allarity Therapeutics, Jensen brings extensive experience and a deep understanding of the company’s DRP® to his new role.
  • Net Loss from Operations: Net Loss from Operations was $17.1 million for 2023, compared to $34 million for 2022.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT

Retrieved on: 
Wednesday, February 28, 2024
Titan, Eli Lilly, Report, News, ALT, Novo Nordisk, Advertising, Patient

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=22535 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Promising Pathways to Simplified Alzheimer's Diagnosis Unveiled in Groundbreaking Study

Retrieved on: 
Wednesday, February 28, 2024
Eli Lilly, African Americans, Merck, IXICO, Person, Research, Collaborative writing, Blood, AbbVie, Diagnosis, Volunteering, Digital technology, Roche, University, Biomarker, GAP, Journal, Disease, Alzheimer's Drug Discovery Foundation, White Americans, Brain, Amyloid plaques, PET, Biogen, Medical imaging

These findings will enhance the field’s ability to provide a more economical, timely, and accurate diagnosis of Alzheimer’s disease and speed enrollment into clinical trials.

Key Points: 
  • These findings will enhance the field’s ability to provide a more economical, timely, and accurate diagnosis of Alzheimer’s disease and speed enrollment into clinical trials.
  • GAP is proud that we succeeded in ensuring that the participants in this study reflected the diverse underrepresented populations afflicted with dementia.
  • With the recent approval of disease-modifying Alzheimer’s treatments, there is a growing need to simplify and accelerate an accurate diagnosis.
  • Dr. Richard Mohs observed that “This paper moves the field ahead in simplifying the diagnosis of Alzheimer’s disease.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT

Retrieved on: 
Saturday, February 24, 2024
Titan, Eli Lilly, Report, News, ALT, Novo Nordisk, Advertising, Patient

The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

Key Points: 
  • The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
  • WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=22535 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Morningstar Indexes Selected by IMX Health for First Healthcare Futures Exchange Product Offering

Retrieved on: 
Tuesday, March 5, 2024
Professional Services, Health, Hospitals, Finance, Pharmaceutical, Biotechnology, Eli Lilly, Hospital, Multimedia, Morningstar, Inc., Growth, Johnson & Johnson, Index, UnitedHealth Group, Health care, Ecosystem, IMX, Contract management, Cryptocurrency

Morningstar, Inc. (Nasdaq: MORN), a leading provider of independent investment insights, today announced that the Intelligent Medicine Exchange (“IMX”), the first futures and options exchange focused on the healthcare economy, has aligned with Morningstar Indexes to offer its first futures product.

Key Points: 
  • Morningstar, Inc. (Nasdaq: MORN), a leading provider of independent investment insights, today announced that the Intelligent Medicine Exchange (“IMX”), the first futures and options exchange focused on the healthcare economy, has aligned with Morningstar Indexes to offer its first futures product.
  • The IMX exchange was designated by the Commodity Futures Trading Commission in January of this year.
  • The new futures product from IMX Health will be based on the Morningstar US Healthcare Index , which measures the performance of approximately 170 U.S. public healthcare companies representing biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term care facilities and medical equipment and supplies.
  • Amelia Furr, global head of sales for Morningstar Indexes, said: “We are excited to offer a Morningstar index as the basis for futures on IMX exchange.